Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 5/2009

01-10-2009 | Review Article

Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists

Authors: Jun Wada, Hirofumi Makino

Published in: Clinical and Experimental Nephrology | Issue 5/2009

Login to get access

Abstract

The most problematic issue in clinical nephrology worldwide is the relentless and progressive increase in patients with end-stage renal disease (ESRD). Diabetic nephropathy has considerable impact on society in the areas of public health and social economy; many scientists are involved in research for the elucidation of the pathogenesis of diabetic nephropathy and for the prevention and cure of the disease. In contrast, diabetic nephropathy was a neglected or ignored disease in the historical era, and few dedicated physicians recognized the disease process of diabetic nephropathy. In this review, we look back on the history of basic and clinical research on diabetic nephropathy and survey the recent progress of the research, especially focusing on the contribution of Japanese scientists.
Literature
1.
Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11(2):156–63.CrossRefPubMed
2.
Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11(1):41–50.CrossRefPubMed
3.
Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) study. Diabetologia. 2005;48(1):17–26.CrossRefPubMed
4.
Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69(11):2057–63.CrossRefPubMed
5.
6.
7.
Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy’s Hosp Rep. 1836;1:336.
8.
9.
10.
Murakami R. Beitrag zum Kennttniss der Veranderung des Nierenkorperchens beim diabetes mellitus. Trans Soc Path Jpn. 1936;26:657.
11.
Spuhler O, Zollinger HU. Die diabetische glomerulosklerose. Deutsch Arch Klin Med. 1943;190:321.
12.
Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Kark RM. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959;38:321–67.CrossRef
13.
Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Maduros W, Kark RM. Structure and function in diabetic nephropathy; the importance of diffuse glomerulosclerosis. Diabetes. 1959;8(4):251–6.CrossRefPubMed
14.
Østerby R, Gundersen HJ. Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia. 1975;11(3):225–9.CrossRefPubMed
15.
Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78.CrossRefPubMed
16.
Nakamoto Y, Takazakura E, Hayakawa H, Kawai K, Dohi K, Fujioka M, et al. Intrarenal microaneurysms in diabetic nephropathy. Lab Invest. 1980;42(4):433–9.PubMed
17.
Saito Y, Kida H, Takeda S, Yoshimura M, Yokoyama H, Koshino Y, et al. Mesangiolysis in diabetic glomeruli: its role in the formation of nodular lesions. Kidney Int. 1988;34(3):389–96.CrossRefPubMed
18.
Yajima G. A histopathological study on diabetic nephropathy—light and electron microscopic observations. Acta Pathol Jpn. 1976;26(1):47–62.PubMed
19.
Nishi S, Ueno M, Hisaki S, Iino N, Iguchi S, Oyama Y, et al. Ultrastructural characteristics of diabetic nephropathy. Med Electron Microsc. 2000;33(2):65–73.CrossRefPubMed
20.
Hayashi H, Karasawa R, Inn H, Saitou T, Ueno M, Nishi S, et al. An electron microscopic study of glomeruli in Japanese patients with non-insulin dependent diabetes mellitus. Kidney Int. 1992;41(4):749–57.CrossRefPubMed
21.
Suzuki Y, Ueno M, Hayashi H, Nishi S, Satou H, Karasawa R, et al. A light microscopic study of glomerulosclerosis in Japanese patients with noninsulin-dependent diabetes mellitus: the relationship between clinical and histological features. Clin Nephrol. 1994;42(3):155–62.PubMed
22.
Ota Z, Shikata K, Ota K. Nephrotic tunnels in glomerular basement membrane as revealed by a new electron microscopic method. J Am Soc Nephrol. 1994;4(12):1965–73.PubMed
23.
Hironaka K, Makino H, Yamasaki Y, Ota Z. Renal basement membranes by ultrahigh resolution scanning electron microscopy. Kidney Int. 1993;43(2):334–45.CrossRefPubMed
24.
Makino H, Yamasaki Y, Haramoto T, Shikata K, Hironaka K, Ota Z, et al. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest. 1993;68(1):45–55.PubMed
25.
Moriya T, Ohno S, Nakazawa K, Shigematsu H, Yajima Y. Ultrastructural study of glomerular basement membrane in diabetic rats by quick-freezing and deep-etching method. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(2):107–14.CrossRefPubMed
26.
Moriya T, Ohno S, Tanaka K, Fujita Y. Clinical applications of the quick-freezing and deep-etching method to human diabetic nephropathy. J Electron Microsc (Tokyo). 2006;55(2):69–73.CrossRef
27.
Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 1997;52(1):111–9.CrossRefPubMed
28.
Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, et al. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes. 1995;44(10):1233–8.CrossRefPubMed
29.
Toyoda M, Suzuki D, Honma M, Uehara G, Sakai T, Umezono T, et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int. 2004;66(3):1107–14.CrossRefPubMed
30.
Kikkawa R, Umemura K, Haneda M, Arimura T, Ebata K, Shigeta Y. Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes. 1987;36(2):240–3.CrossRefPubMed
31.
Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes. 1997;46(5):847–53.CrossRefPubMed
32.
Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14(3):439–47.CrossRefPubMed
33.
Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 2000;49(6):1022–32.CrossRefPubMed
34.
Ishida T, Haneda M, Maeda S, Koya D, Kikkawa R. Stretch-induced overproduction of fibronectin in mesangial cells is mediated by the activation of mitogen-activated protein kinase. Diabetes. 1999;48(3):595–602.CrossRefPubMed
35.
Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325(12):836–42.CrossRefPubMed
36.
Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int. 1995;48(2):517–26.CrossRefPubMed
37.
Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 1997;100(12):2995–3004.CrossRefPubMedPubMedCentral
38.
Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 1994;343(8912):1519–22.CrossRefPubMed
39.
Mitsuhashi T, Nakayama H, Itoh T, Kuwajima S, Aoki S, Atsumi T, et al. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes. 1993;42(6):826–32.CrossRefPubMed
40.
Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem. 2002;277(23):20309–15.CrossRefPubMed
41.
Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108(2):261–8.CrossRefPubMedPubMedCentral
42.
Uesugi N, Sakata N, Horiuchi S, Nagai R, Takeya M, Meng J, et al. Glycoxidation-modified macrophages and lipid peroxidation products are associated with the progression of human diabetic nephropathy. Am J Kidney Dis. 2001;38(5):1016–25.CrossRefPubMed
43.
Fukuhara-Takaki K, Sakai M, Sakamoto Y, Takeya M, Horiuchi S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J Biol Chem. 2005;280(5):3355–64.CrossRefPubMed
44.
Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y, et al. Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int. 1996;49(4):1120–6.CrossRefPubMed
45.
Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest. 1993;92(6):2597–601.CrossRefPubMedPubMedCentral
46.
Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 1999;55(2):465–75.CrossRefPubMed
47.
Haneda M, Kikkawa R, Koya D, Uzu T, Maeda S, Togawa M, et al. Alteration of mesangial response to ANP and angiotensin II by glucose. Kidney Int. 1993;44(3):518–26.CrossRefPubMed
48.
Haneda M, Kikkawa R, Maeda S, Togawa M, Koya D, Horide N, et al. Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int. 1991;40(2):188–94.CrossRefPubMed
49.
Kikkawa R, Haneda M, Sakamoto K, Koya D, Shikano T, Nakanishi S, et al. Antagonist for atrial natriuretic peptide receptors ameliorates glomerular hyperfiltration in diabetic rats. Biochem Biophys Res Commun. 1993;193(2):700–5.CrossRefPubMed
50.
Makino H, Mukoyama M, Mori K, Suganami T, Kasahara M, Yahata K, et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia. 2006;49(10):2514–24.CrossRefPubMed
51.
Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia. 1998;41(12):1426–34.CrossRefPubMed
52.
Hiragushi K, Wada J, Eguchi J, Matsuoka T, Yasuhara A, Hashimoto I, et al. The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocin-induced diabetic rats. Kidney Int. 2004;65(2):540–50.CrossRefPubMed
53.
Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes. 2004;53(7):1831–40.CrossRefPubMed
54.
Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 2005;54(10):2891–903.CrossRefPubMed
55.
Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K, Kitayama H, et al. 2-(8-hydroxy-6-methoxy-1-oxo-1h–2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006;55(5):1232–42.CrossRefPubMed
56.
Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis. 1993;21(5):480–5.CrossRefPubMed
57.
Sugimoto H, Shikata K, Hirata K, Akiyama K, Matsuda M, Kushiro M, et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes. 1997;46(12):2075–81.CrossRefPubMed
58.
Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003;52(10):2586–93.CrossRefPubMed
59.
Usui HK, Shikata K, Sasaki M, Okada S, Matsuda M, Shikata Y, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes. 2007;56(2):363–72.CrossRefPubMed
60.
Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003;18(2):265–72.CrossRefPubMed
61.
Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-{kappa}B activation. Am J Physiol Renal Physiol. 2007;292(4):F1141–50.CrossRefPubMed
62.
Yozai K, Shikata K, Sasaki M, Tone A, Ohga S, Usui H, et al. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol. 2005;16(11):3326–38.CrossRefPubMed
63.
Tone A, Shikata K, Sasaki M, Ohga S, Yozai K, Nishishita S, et al. Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia. 2005;48(11):2402–11.CrossRefPubMed
64.
Miyata T, Nangaku M, Suzuki D, Inagi R, Uragami K, Sakai H, et al. A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J Clin Invest. 1998;102(4):828–36.CrossRefPubMedPubMedCentral
65.
Inagi R, Yamamoto Y, Nangaku M, Usuda N, Okamato H, Kurokawa K, et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes. 2006;55(2):356–66.CrossRefPubMed
66.
Wada J, Kanwar YS. Characterization of mammalian translocase of inner mitochondrial membrane (Tim44) isolated from diabetic newborn mouse kidney. Proc Natl Acad Sci USA. 1998;95(1):144–9.CrossRefPubMedPubMedCentral
67.
Yang Q, Dixit B, Wada J, Tian Y, Wallner EI, Srivastva SK, et al. Identification of a renal-specific oxido-reductase in newborn diabetic mice. Proc Natl Acad Sci USA. 2000;97(18):9896–901.CrossRefPubMedPubMedCentral
68.
Matsuoka T, Wada J, Hashimoto I, Zhang Y, Eguchi J, Ogawa N, et al. Gene delivery of Tim44 reduces mitochondrial superoxide production and ameliorates neointimal proliferation of injured carotid artery in diabetic rats. Diabetes. 2005;54(10):2882–90.CrossRefPubMed
69.
Zhang Y, Wada J, Hashimoto I, Eguchi J, Yasuhara A, Kanwar YS, et al. Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production. J Am Soc Nephrol. 2006;17(4):1090–101.CrossRefPubMed
70.
Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006;55(6):1666–77.CrossRefPubMed
71.
Nagai K, Arai H, Yanagita M, Matsubara T, Kanamori H, Nakano T, et al. Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem. 2003;278(20):18229–34.CrossRefPubMed
72.
Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 2005;68(2):552–61.CrossRefPubMed
73.
74.
Yanagita M. The role of the vitamin K-dependent growth factor Gas6 in glomerular pathophysiology. Curr Opin Nephrol Hypertens. 2004;13(4):465–70.CrossRefPubMed
75.
Suganami T, Mukoyama M, Mori K, Yokoi H, Koshikawa M, Sawai K, et al. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J. 2005;19(1):127–9.CrossRefPubMed
76.
Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes. 2005;54(4):1171–8.CrossRefPubMed
77.
Tanaka N, Babazono T, Saito S, Sekine A, Tsunoda T, Haneda M, et al. Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes. 2003;52(11):2848–53.CrossRefPubMed
78.
Hayashi Y, Makino H, Ota Z. Serum and urinary concentrations of type IV collagen and laminin as a marker of microangiopathy in diabetes. Diabet Med. 1992;9(4):366–70.CrossRefPubMed
79.
Okonogi H, Nishimura M, Utsunomiya Y, Hamaguchi K, Tsuchida H, Miura Y, et al. Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol. 2001;55(5):357–64.PubMed
80.
Tomino Y, Suzuki S, Azushima C, Shou I, Iijima T, Yagame M, et al. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal. 2001;15(4):188–92.CrossRefPubMed
81.
Yoshikawa R, Wada J, Seiki K, Matsuoka T, Miyamoto S, Takahashi K, et al. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;76(3):358–67.CrossRefPubMed
82.
Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005;28(11):2728–32.CrossRefPubMed
83.
Nakamura T, Sugaya T, Koide H. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure. Diabetologia. 2007;50(2):490–2.CrossRefPubMed
84.
Suzuki K, Babazono T, Murata H, Iwamoto Y. Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy. Diabetes Care. 2005;28(8):2038–9.CrossRefPubMed
85.
Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313(26):1617–20.CrossRefPubMed
86.
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–17.CrossRefPubMed
87.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577–8.CrossRefPubMed
88.
Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007;30(6):1581–3.CrossRefPubMed
89.
Araki SI, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes mellitus. Diabetes. 2007;56(6):1727–30.CrossRefPubMed
Metadata
Title
Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists
Authors
Jun Wada
Hirofumi Makino
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0175-5

Other articles of this Issue 5/2009

Clinical and Experimental Nephrology 5/2009 Go to the issue

Original Article

Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort

Original Article

Six-year dialysis freedom in end-stage renal disease

Original Article

Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats

Original Article

Microwave tissue coagulator induces renal apoptotic damage to preserved normal renal tissue following partial nephrectomy

Case Report

Fatal hemoperitoneum due to rupture of the left gastric artery in a patient with microscopic polyangiitis

Case Report

Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits